Neurological problems in the elderly

Reichel's Care of the Elderly: Clinical Aspects of Aging, Sixth Edition

Volumn , Issue , 2009, Pages 140-170

  Zawora, Michele ^a   Liang, Tsoa Wei ^b   Jarra, Hadijatou ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953844790     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511575952.015     Document Type: Chapter

References (53)

1. Verghese J, Le Valley A, Hall, CB, Katz MJ, Ambrose AF, Lipton RB. Epidemiology of gait disorders in community-residing older adults. J Am Geriatr Soc. 2006; 54: 255-261.
2. Sudarsky LR. Gait impairment and falls. In: Principles of Ambulatory Neurology and the Approach to Clinical Problems. 25-28.
3. Ruzicka E, Jankovic JJ. Disorders of gait. In: Parkinson's Disease and Movement Disorders. 409-429.
4. Mouton CP, Espino DV. Health screening in older women. Am Fam Physician. 1999; 59: 1835-1842.
5. Barak Y, Wagenaar RC, Holt KG. Gait characteristic of elderly people with a history of falls: a dynamic approach. Phys Ther. 2006; 86: 1501-1510.
6. Gilman S. Merritt's Neurology. 10th ed. Philadelphia: Lippincott Williams &Wilkins; 2000.
7. Baddour RJ, Wolfson L. Nervous system disease. In: Duthie EH, Katz PR. (eds). Duthie: Practice of Geriatrics. 3rd ed. Philadelphia: WB. Saunders; 1998: 317-327.
8. Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet. 2000; 355(9213): 1441-1446.
9. Waterhouse E, Towne A. Seizures in the elderly: Nuances in presentation and treatment. ClevelandClin JMed. 2005; 72(Suppl 3): S26-S37.
10. Arroyo S. Treating epilepsy in the elderly. Drug Safety. 2001; 24: 991-1015.
11. Cloyd J, HauserW, Towne A, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006; 68(Suppl 1): 39-48.
12. Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging. 2004; 21: 639-653.
13. Mendez MF, Lim GTH. Seizures in elderly people with dementia: epidemiology and management. Drugs Aging. 2003; 20: 791-803.
14. Glauser T, Ben-Menchem E. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006; 47: 1094-1120.
15. BergeyGK. Initial treatment of epilepsy. Neurology. 2004; 63: S40-S48.
16. Morgan GW. Proprioception, touch, and vibratory sensation. In: Goetz CG, Pappert EJ. (ed). Goetz: Textbook of Clinical Neurology. 2nd ed. Philadelphia: WB Saunders; 2003: 315-332.
17. Mold JW, Vesely SK, Keyl BA. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract. 2004; 17: 309-318.
18. Bastyr EJ, Price KL, Bril V. Development and validity testing of the neuropathy total symptom score 6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005; 27: 1278-1294.
19. Lozeron P. Symptomatic diabetic and non-diabetic neuropathies in a series of 100 diabetic patients. J Neurol. 2002; 249: 569-575.
20. Koopman RJ, Mainous AG, Liszka HA, et al. Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med. 2006; 4: 427-432.
21. Oh RC. Vitamin B12 deficiency. Am Fam Physician. 2003; (67): 979-994.
22. Hughes, RAC. Peripheral neuropathy. BMJ. 2002; 324: 466-469.
23. Dworkin RJ, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003; 60: 1524-1534.
24. Pascuzzi RM. Peripheral neuropathies in clinical practice. Med Clin N Am. 2003; 87: 697-724.
25. Stillman M. Clinical approach to patientswith neuropathic pain. Cleveland Clin J Med. 2006; 73: 726-739.
26. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord. 1998; 13: 5-10.
27. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord. 1997; 12: 859-864.
28. Glucher JR, Jonsson P, Kong A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nat Genet. 1997; 17: 84-87.
29. KollerWC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Essential Tremor Study Group. Ann Neurol. 1994; 35: 717-723.
30. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005; 64: 2008-2020.
31. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997; 42: 292-299.
32. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. NEJM. 2000; 342: 461-468.
33. Tyrer P, Alexander MS, Regan A, Lee I. An extrapyramidal syndrome after lithium therapy. Br J Psychiatry. 1980; 136: 191-194.
34. Niethammer M, Ford B. Permanent lithium-induced cerebellar toxicity: Three cases and review of literature. Mov Disord. 2007; 22: 570-573.
35. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. AdHoc ScientificCommittee. Mov Disord. 1998; 13(Suppl 3): 2-23.
36. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993; 50: 140-148.
37. Winikates J, Jankovic J. Clinical correlates of vascular Parkinsonism. Arch Neurol. 1999; 56: 98-102.
38. Langston JW, Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci. 1984; 11: 160-165.
39. OlanowCW. Manganese-induced Parkinsonism and Parkinson's disease. Ann NY Acad Sci. 2004; 1012: 209-223.
40. KlawansHL, Stein RW, Tanner CM, Goetz CG. A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch Neurol. 1982; 39: 302-304.
41. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. NEJM. 1993; 328: 176-183.
42. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002; 59: 1541-1550.
43. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REALPET study. Ann Neurol. 2003; 54: 93-101.
44. [Anonymous]. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002; 287: 1653-1661.
45. The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 2002; 59: 1937-1943.
46. CalneDB. The role of various forms of treatment in themanagement of Parkinson's disease. ClinNeuropharmacol. 1982; 5(Suppl 1): S38-S43.
47. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002; 77: 1280-1286.
48. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. O56 study group. NEJM. 2000; 342: 1484-14891.
49. [Anonymous]. Pramipexole vs levodopa as initial treatment for parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000; 284: 1931-1938.
50. Rinne UK, Rinne JO, Rinne JK, Laakso K, Laihinen A, Lonnberg P. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J Neural Transm Suppl. 1983; 18: 279-286.
51. MouradianMM, Heuser IJ, Baronti F, ChaseTN. Modification of central dopiminergic mechanisms by continuous levodopa therapy for advancedParkinson's disease. AnnNeurol. 1990; 27: 18-23.
52. Block G, Liss C, Reines S, Irr J, Nibberlink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. Amulticenter 5-year study. theCRfirst study group. Eur Neurol. 1997; 37: 23-27.
53. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa inParkinsonian patients. Neurology. 1994; 44: 913-919.